BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25139548)

  • 1. Is postoperative computed tomography evaluation a prognostic indicator in patients with optimally debulked advanced ovarian cancer?
    Lorusso D; Sarno I; Di Donato V; Palazzo A; Torrisi E; Pala L; Marchiano A; Raspagliesi F
    Oncology; 2014; 87(5):293-9. PubMed ID: 25139548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
    Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
    AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
    Chi DS; Barlin JN; Ramirez PT; Levenback CF; Mironov S; Sarasohn DM; Iyer RB; Dao F; Hricak H; Barakat RR
    Int J Gynecol Cancer; 2010 Apr; 20(3):353-7. PubMed ID: 20375796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings.
    Kim HJ; Choi CH; Lee YY; Kim TJ; Lee JW; Bae DS; Kim BG
    Taiwan J Obstet Gynecol; 2014 Sep; 53(3):343-7. PubMed ID: 25286788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
    Chi DS; Ramirez PT; Teitcher JB; Mironov S; Sarasohn DM; Iyer RB; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Brown CL; Aghajanian C; Gershenson DM; Hoskins WJ; Hricak H; Barakat RR
    J Clin Oncol; 2007 Nov; 25(31):4946-51. PubMed ID: 17971592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Eskander RN; Kauderer J; Tewari KS; Mannel RS; Bristow RE; O'Malley DM; Rubin SC; Glaser GE; Hamilton CA; Fujiwara K; Huh WK; Ueland F; Stephan JM; Burger RA
    Gynecol Oncol; 2018 Jun; 149(3):525-530. PubMed ID: 29550184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer.
    Burger IA; Goldman DA; Vargas HA; Kattan MW; Yu C; Kou L; Andikyan V; Chi DS; Hricak H; Sala E
    Gynecol Oncol; 2015 Sep; 138(3):554-9. PubMed ID: 26093061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer.
    Sala E; Mannelli L; Yamamoto K; Griffin M; Griffin N; Grant L; Parker R; Crawford R
    Int J Gynecol Cancer; 2011 Feb; 21(2):296-301. PubMed ID: 21721161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
    Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
    Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
    Lim H; In Shim J; Park SJ; Noh J; Kim TM; Lee M; Choi CH; Chung HH; Kim TJ; Lee JW; Kim JW; Kim BG; Park NH; Song YS; Kim SY; Park SY; Kim HS; Lee YY
    Gynecol Oncol; 2022 Jun; 165(3):493-499. PubMed ID: 35367074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer.
    Kolev V; Mironov S; Mironov O; Ishill N; Moskowitz CS; Gardner GJ; Levine DA; Hricak H; Barakat RR; Chi DS
    Int J Gynecol Cancer; 2010 Aug; 20(6):979-84. PubMed ID: 20683405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
    Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
    Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.
    Axtell AE; Lee MH; Bristow RE; Dowdy SC; Cliby WA; Raman S; Weaver JP; Gabbay M; Ngo M; Lentz S; Cass I; Li AJ; Karlan BY; Holschneider CH
    J Clin Oncol; 2007 Feb; 25(4):384-9. PubMed ID: 17264334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive value of preoperative abdominopelvic CT for optimal cytoreduction surgery in ovarian carcinoma].
    Taïeb S; Bonodeau F; Leblanc é ; Vennin P; Fournier C; Besson P
    Bull Cancer; 2000 Mar; 87(3):265-72. PubMed ID: 10779815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.